Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.218 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Assets: | |||||
| Current Assets: | |||||
| Cash & Cash Equivalents
| 735.864 | 1,607.409 | 2,767.371 | 516.184 | 148.694 |
| Short Term Investments
| 30.393 | 33.172 | 98.796 | 290.328 | 10 |
| Cash and Short Term Investments
| 766.257 | 1,640.581 | 2,866.167 | 806.512 | 158.694 |
| Net Receivables
| 24.106 | -13.929 | -30.908 | -20 | 0 |
| Inventory
| 696.978 | 2,384.34 | 768.691 | 50.881 | 0.393 |
| Other Current Assets
| 426.343 | 395.237 | 1,479.345 | 211.032 | 5.259 |
| Total Current Assets
| 1,899.519 | 4,389.929 | 5,076.495 | 1,048.425 | 164.346 |
| Non-Current Assets: | |||||
| Property, Plant & Equipment, Net
| 162.056 | 241.744 | 222.403 | 86.987 | 17.428 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 39.859 | 34.998 | 13.828 | 0.277 | 0.294 |
| Goodwill and Intangible Assets
| 39.859 | 34.998 | 13.828 | 0.277 | 0.294 |
| Long Term Investments
| -14.165 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 14.165 | 28.035 | 32.934 | 51.839 | 4.148 |
| Total Non-Current Assets
| 201.915 | 304.777 | 269.165 | 139.103 | 21.87 |
| Total Assets
| 2,101.434 | 4,694.706 | 5,345.66 | 1,187.528 | 186.216 |
| Liabilities & Equity: | |||||
| Current Liabilities: | |||||
| Account Payables
| 247.829 | 856.964 | 588.559 | 33.82 | 7.165 |
| Short Term Debt
| 326.598 | 317.63 | 21.48 | 4.259 | 1.81 |
| Tax Payables
| 3.067 | 6.284 | 5.919 | 1.422 | 0.083 |
| Deferred Revenue
| 1,702.051 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 0.525 | 1,654.611 | 1,538.07 | 28.655 | 18.512 |
| Total Current Liabilities
| 2,277.003 | 2,829.205 | 2,148.109 | 66.734 | 27.487 |
| Non-Current Liabilities: | |||||
| Long Term Debt
| 7.853 | 36.738 | 46.44 | 18.057 | 10.645 |
| Deferred Revenue Non-Current
| 44.364 | 2,496.9 | 1,931.963 | 958.172 | 17.17 |
| Deferred Tax Liabilities Non-Current
| -44.364 | -2,496.9 | -1,931.963 | 0 | 0 |
| Other Non-Current Liabilities
| 549.411 | 2,496.9 | 1,931.963 | 1,127.306 | 198.736 |
| Total Non-Current Liabilities
| 557.264 | 2,533.638 | 1,978.403 | 2,103.535 | 226.551 |
| Total Liabilities
| 2,834.267 | 5,362.843 | 4,126.512 | 2,170.269 | 254.038 |
| Equity: | |||||
| Preferred Stock
| 9,640.268 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.838 | 0.835 | 0.742 | 0 | 0 |
| Retained Earnings
| -9,640.268 | -9,501.729 | -7,049.826 | -1,033.523 | -120.625 |
| Accumulated Other Comprehensive Income/Loss
| -733.641 | 270.383 | 296.632 | 50.782 | 52.803 |
| Other Total Stockholders Equity
| -0.03 | 8,562.374 | 7,971.6 | 0 | 0 |
| Total Shareholders Equity
| -732.833 | -668.137 | 1,219.148 | -982.741 | -67.822 |
| Total Equity
| -732.833 | -668.137 | 1,219.148 | -982.741 | -67.822 |
| Total Liabilities & Shareholders Equity
| 2,101.434 | 4,694.706 | 5,345.66 | 1,187.528 | 186.216 |